System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Xavier Montalban is an expert in Neurology at Vall d'Hebron Hospital Universitari (Spain). As of October 2026, ScienceLeadR ranks Xavier Montalban in the top 1% of experts worldwide for Multiple Sclerosis, Primary Progressive Multiple Sclerosis and Autoimmune Diseases. Xavier Montalban has authored 1,218 publications, the most recent in 2026, and is an investigator in 57 clinical trials, 1 of them ongoing. SLR score: 4,095 (community average: 125). How the SLR is computed.

LeadR Profile

Xavier Montalban Vall d'Hebron Hospital Universitari Spain
4 095 ScienceLeadR Reputation 4095

Unlock

Register Login
Network Map

Neurology

Subspecialties: Immunology - Biochemistry - Internal Medicine

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1996 - 2026
Source: PubMed

Vall d'Hebron Hospital Universitari

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 1218

Citations

Citations: 83 634 1st author: 58 Last author: 255 Unique author: 14

Main journals

Neurology 229
Mult Scler 178
J Neurol 52
J Neurol Neurosurg Psychiatry 43
Lancet Neurol 43

Best Journals

Lancet Neurol 18
N Engl J Med 16
Lancet 5

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Education Research: Career, Research, and Mentorship Outcomes of an International Neuroimmunology Education Exchange Program.
PMID 42893117 — odds ratio, research, neurologists, education		Neurol Educ20260
Ten Years of Ocrelizumab in Relapsing Multiple Sclerosis: The OPERA I and II Randomized Clinical Trials.
PMID 42832215 — sclerosis, multiple sclerosis, interferon-beta, therapeutics, nervous system diseases		JAMA Neurol20260
Age and treatment class modify inflammatory risk after disease-modifying therapy discontinuation in older people with MS.
PMID 42735930 — aged, therapeutics, neurology		J Neurol Neurosurg Psychiatry20260
Evaluation of the 2022 international consensus criteria for optic neuritis: the role of clinical features and visual evoked potentials.
PMID 42696026 — evoked potentials, laboratories, neuritis, neurosurgery, optic neuritis, diagnosis, neurology, evoked potentials, visual		J Neurol20260
[XVIII Post-ECTRIMS Meeting: Review of the New Developments Presented at the 2025 ECTRIMS Congress (Part I)].
PMID 42689738 — cells, multiple sclerosis, spinal cord, biomarkers, neuromyelitis optica, diagnosis, therapeutics, neurology, spine		Rev Neurol20260

Clinical Studies 57

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1

By phase:

Phase 3 23
Phase 2 18
Phase 4 8
N/A 4
Phase 1 3
Phase 1/Phase 2 1

By status:

Completed 46
Terminated 6
Active not recruiting 4
Suspended 1

By type:

Interventional 56
Observational 1

By Monocentric/Multicentric:

monocentric 5
multicentric2to4 2
multicentric5to9 2
multicentricup10 48

Main Topics

Cohort/Consortium Investigators 6

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Proof of concept Study for SAR441344 (Frexalimab) in Relapsing Multiple Sclerosis
NCT04879628 — injections, sclerosis, multiple sclerosis, safety, pharmaceutical preparations, solutions, proof of concept study, cd40 ligand, antibodies, monoclonal		Phase 2Active not recruiting2021

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS